Evidence map›Paper›PMID 39847602›Full record

ArticlePLOS digital health2025

Quality of life disparities among Mexican people with systemic lupus erythematosus.

Ana Laura Hernández-Ledesma, Domingo Martínez, Elizabeth Fajardo-Brigido, Talía V Román-López, Karen J Nuñez-Reza, Andrea Y Tapia-Atilano, Sandra V Vera Del Valle, Donají Domínguez-Zúñiga, Lizbet Tinajero-Nieto, Angélica Peña-Ayala and 9 more

Abstract read
In one paragraph

Article in PLOS digital health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Ana Laura Hernández-LedesmaLaboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Campus Juriquilla, Blvd Juriquilla 3001, 76230 Santiago de Querétaro, México.ORCID https://orcid.org/0000-0002-8819-7471
Domingo MartínezLaboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Campus Juriquilla, Blvd Juriquilla 3001, 76230 Santiago de Querétaro, México.
Elizabeth Fajardo-BrigidoInstituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, Morelos, México.
Talía V Román-LópezDepartamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Juriquilla, Querétaro, México.
Karen J Nuñez-RezaLaboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Campus Juriquilla, Blvd Juriquilla 3001, 76230 Santiago de Querétaro, México.
Andrea Y Tapia-AtilanoLaboratorio de Neurogenómica Cognitiva, Unidad de Psicobiología y Neurociencias, Coordinación de Psicobiología y Neurociencias. Facultad de Psicología, Universidad Nacional Autónoma de México, Coyoacán, Ciudad de México, México.
Sandra V Vera Del ValleFacultad de Medicina, Universidad Autónoma de Durango, Querétaro, México.
Donají Domínguez-ZúñigaPrivate practice, Cuernavaca, Morelos, México.
Lizbet Tinajero-NietoHospital General Regional No. 1, Instituto Mexicano del Seguro Social, Querétaro, México.
Angélica Peña-AyalaHospital General Regional No. 1, Instituto Mexicano del Seguro Social, Querétaro, México.
Estefania Torres-ValdezHospital General Regional No. 2, Instituto Mexicano del Seguro Social, Querétaro, México.
Gabriel Frontana-VázquezHospital General Regional No. 2, Instituto Mexicano del Seguro Social, Querétaro, México.
María Gutiérrez-ArcelusDivision of Immunology, Boston Children's Hospital, Boston, Massachusetts, United States of America.
Florencia RosettiDepartamento de Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Tlalpan, Ciudad de México, México.
Sarael AlcauterDepartamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Juriquilla, Querétaro, México.
Miguel E RenteríaMental Health & Neuroscience Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Alejandra E Ruiz-ContrerasLaboratorio de Neurogenómica Cognitiva, Unidad de Psicobiología y Neurociencias, Coordinación de Psicobiología y Neurociencias. Facultad de Psicología, Universidad Nacional Autónoma de México, Coyoacán, Ciudad de México, México.ORCID https://orcid.org/0000-0002-9829-7636
Deshiré Alpízar-RodríguezCentro Médico Althea, Morelos, México.
Alejandra Medina-RiveraLaboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Campus Juriquilla, Blvd Juriquilla 3001, 76230 Santiago de Querétaro, México.ORCID https://orcid.org/0000-0002-7912-2718

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Higher prevalence and worst outcome have been reported among people with systemic lupus erythematosus with non-European ancestries, with both genetic and socioeconomic variables as contributing factors. In Mexico, studies assessing the inequities related to quality of life for Systemic Lupus Erythematosus patients remain sparse. This study aims to assess the inequities related to quality of life in a cohort of Mexican people with SLE. This study included 942 individuals with SLE from the Mexican Lupus Registry (LupusRGMX) and two healthy control groups. Self-answered surveys were collected via the Research Electronic Data Capture platform between May 2021 and January 2023. Data was analyzed as a cross-sectional study. A random forest model was implemented to assess potential predictive variables. Permutation tests were performed to analyze the effect health providers had on diagnosis lag and quality of life's differences among socioeconomic levels. Partial correlation analysis between the number of patients and rheumatologists registered was also performed. Systemic Lupus Erythematosus participants had significantly lower quality of life than healthy people (p-values < 0.0001). Socioeconomic status, delay in diagnosis, and corticosteroid consumption were the factors that influenced QoL the most (RMSE = 9.53 with the importance variable validated); lower quality of life was associated with lower socioeconomic status (p-value < 0.0001). Disparities in health services were reflected in longer diagnosis time among people with public health providers (p-value = 0.0419). A significant association between diagnosed patients and available rheumatologists by geographical state was observed (ρ = 0.4, p-value = 0.0259), which can be translated into restricted access to specialists. Since most of our cohort exhibited low socioeconomic status, it is important to consider them as a vulnerable population; this study settles the necessity to deepen the effects of the socioeconomic disparities, allowing to design public policies and strategies aimed to reduce Systemic Lupus Erythematosus disparities, therefore improving quality of life of Mexican people with Systemic Lupus Erythematosus.

Identifiers

PMID39847602
PMCPMC11756751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.